The first challenge is going to be passing the Section 2 of the Sherman Act, which is designed to attack monopolies, due to the fact that if they combine, they will have power to fix prices or exclude competitors from a pharmaceutical market. However, the Section 2 considers the act of monopolizing, thus, their monopoly power, which resulted from combination, is not enough to be guilty because there must be an intent to monopolize the market. For this reason, Pfizer and Allergen should convince the court that they will be acquired a dominant market position through superior products or other demos. Another challenge will be the Section 7 of The Claytn Act, which designed to attack to mergers, but the court considers horizontal merger (between
